1. Rigosertib in Combination with Azacitidine Modulates Epigenetic Pathways and can Overcome Clinical Resistance to Hypomethylating Agents in Myelodysplastic Syndromes (MDS). (April 2017) Authors: Chaurasia, P.; Isoda, F.; Navada, S.; Odchimar-Reissig, R.; Demakos, E.P.; Reddy, E.P.; Silverman, L.R. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S121 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗